checkAd

    EQS-News  221  0 Kommentare Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

    Für Sie zusammengefasst
    • Newron Pharmaceuticals Investor Day on June 25, 2024 in NYC
    • Leading KOLs in neuroscience to review evenamide program
    • Focus on clinical, scientific, and commercial plans for schizophrenia

    EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous
    Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

    18.06.2024 / 17:45 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City  

    Three of the world’s leading key opinion leaders (KOL) in neuroscience and schizophrenia to review and present findings on Newron’s evenamide program for treatment-resistant schizophrenia  

    The company will host a Live-Webcast of the event, beginning at 9:00 AM EDT (2:00 PM GMT, 3:00 PM CEST)

    Milan, Italy and Morristown, NJ, USA – June 18, 2024 - Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00-11:00 AM EDT.

    This comprehensive research and investor update event will focus on Newron’s clinical, scientific and commercial plans for evenamide for chronic and treatment-resistant schizophrenia.

    Three of the leading KOLs in neuroscience and schizophrenia will review Newron’s Phase III evenamide program and explore the unmet needs, new concepts and recent neurobiological findings for treating poor responders and patients with treatment-resistant schizophrenia (TRS).

    These leading experts in psychiatry and schizophrenia are:

    Anthony Grace, Ph.D., is Editor-in-Chief, International Journal of Neuropsychopharmacology, Distinguished Professor of Neuroscience, and Professor of Psychiatry and Psychology at the University of Pittsburgh. Dr. Grace will present breakthrough pre-clinical data on treatment-resistant schizophrenia:

    Evenamide can exert unique efficacy in schizophrenia by targeting the site of pathology: preclinical evidence supports effects seen in patients with TRS

    John Kane, M.D., Co-Director & Professor, Institute of Behavioural Science,

    Feinstein Institutes for Medical Research, and Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. One of the leading researchers in the field of schizophrenia, Dr. Kane will address the topic:

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City 18.06.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer